Sana Biotechnology (NASDAQ:SANA) Hits New 1-Year Low – Here’s What Happened

Posted by George Bondi on Oct 14th, 2026

Sana Biotechnology, Inc. (NASDAQ:SANA – Get Free Report)’s stock price hit a new 52-week low during trading on Monday. The company traded as low as $2.61 and last traded at $2.6050, with a volume of 1,744,170 shares changing hands. The stock had previously closed at $2.79.

Wall Street Analysts Forecast Growth

SANA has been the subject of a number of recent analyst reports. Wall Street Zen downgraded Sana Biotechnology from a “hold” rating to a “sell” rating in a report on Monday, July 20th. Bank of America dropped their target price on shares of Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Weiss Ratings upgraded shares of Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 23rd. Finally, TD Cowen raised Sana Biotechnology to a “strong-buy” rating in a report on Monday, August 24th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $9.33.

Get Our Latest Analysis on Sana Biotechnology

Sana Biotechnology Price Performance

The company has a 50-day simple moving average of $3.37 and a 200-day simple moving average of $3.30. The stock has a market cap of $696.01 million, a PE ratio of -3.07 and a beta of 2.18.

Sana Biotechnology (NASDAQ:SANA – Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.02. On average, equities analysts expect that Sana Biotechnology, Inc. will post -0.72 EPS for the current fiscal year.

Institutional Trading of Sana Biotechnology

Institutional investors and hedge funds have recently bought and sold shares of the business. Sequoia Financial Advisors LLC purchased a new stake in Sana Biotechnology during the 2nd quarter worth $54,000. WINTON GROUP Ltd purchased a new position in Sana Biotechnology in the second quarter valued at about $99,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Sana Biotechnology during the 2nd quarter worth approximately $359,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Sana Biotechnology by 22.8% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 284,472 shares of the company’s stock valued at $993,000 after purchasing an additional 52,766 shares in the last quarter. Finally, Hsbc Holdings PLC boosted its stake in shares of Sana Biotechnology by 55.1% during the 2nd quarter. Hsbc Holdings PLC now owns 111,959 shares of the company’s stock valued at $392,000 after buying an additional 39,765 shares during the last quarter. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

(Get Free Report)

Sana Biotechnology, Inc is a biotechnology company focused on developing engineered cell and gene therapies intended to treat diseases with significant unmet medical needs. The company’s approach is designed to enable the delivery of functional cells or genetic material to patients while addressing challenges such as immune rejection, manufacturing complexity and the need for repeated treatment.

Sana’s research programs include both ex vivo therapies, in which cells are modified outside the body before being administered to a patient, and in vivo therapies, which are designed to modify or deliver therapeutic material directly within the body.